2-hydroxy-4-methoxychalcone inhibits proliferation and inflammation of human aortic smooth muscle cells by increasing the expression of peroxisome proliferator-activated receptor gamma

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 4, 2012, Pages 339-351

  Liu, Chin San ^a   Chang, Chen Chia ^b   Du, Ying Chi ^c   Chang, Fang Rong ^c,d,e   Wu, Yang Chang ^c,f,g   Chang, Wei Chiao ^b   Hsieh, Tusty Jiuan ^b  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c Graduate Institute of Natural Products   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

atherosclerosis; chalcone; flavonoid; IL 6; Ox LDL; PPARg

Indexed keywords

2 HYDROXY 4' METHOXYCHALCONE; AN 07; CHALCONE DERIVATIVE; CYCLIN D1; CYCLIN D3; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; AORTA MEDIA; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; INHIBITION KINETICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; UPREGULATION; WESTERN BLOTTING;

AORTA; ATHEROSCLEROSIS; CELL CYCLE; CELL PROLIFERATION; CHALCONES; DRUG SYNERGISM; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84859882663     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182440486     Document Type: Article

References (38)

1. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104: 503-516. (Pubitemid 32201946)
2. Barton M, Minotti R, Haas E. Inflammation and atherosclerosis. Circ Res. 2007;101:750-751. (Pubitemid 350287187)
3. Metharom P, Caplice NM. Vascular disease: a new progenitor biology. Curr Vasc Pharmacol. 2007;5:61-68.
4. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995;75:487-517.
5. Singer CA, Salinthone S, Baker KJ, et al. Synthesis of immune modulators by smooth muscles. Bioessays. 2004;26:646-655. (Pubitemid 38758342)
6. Pidkovka NA, Cherepanova OA, Yoshida T, et al. Oxidized phospholipids induce phenotypic switching of vascular smooth muscle cells in vivo and in vitro. Circ Res. 2007;101:792-801. (Pubitemid 350287194)
7. Batovska DI, Todorova IT. Trends in utilization of the pharmacological potential of chalcones. Curr Clin Pharmacol. 2010;5:1-29.
8. Mulvihill EE, Huff MW. Antiatherogenic properties of flavonoids: implications for cardiovascular health. Can J Cardiol. 2010;26:17A-21A.
9. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000;14:121-141. (Pubitemid 30070977)
10. Martin H. Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components. Mutat Res. 2010;690:57-63.
11. van Bilsen M, van Nieuwenhoven FA. PPARs as therapeutic targets in cardiovascular disease. Expert Opin Ther Targets. 2010;14:1029-1045.
12. Hsueh WA, Law RE. PPARg and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol. 2001;21:1891-1895. (Pubitemid 34219737)
13. Regieli JJ, Jukema JW, Doevendans PA, et al. PPAR gamma variant influences angiographic outcome and 10-year cardiovascular risk in male symptomatic coronary artery disease patients. Diabetes Care. 2009;32: 839-844.
14. Chahine MN, Blackwood DP, Dibrov E, et al. Oxidized LDL affects smooth muscle cell growth through MAPK-mediated actions on nuclear protein import. J Mol Cell Cardiol. 2009;46:431-441.
15. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009;78:539-552.
16. Wakino S, Kintscher U, Kim S, et al. Peroxisome-proliferator activated receptor-g ligands inhibit Rb phosphorylation and G13S transition in vascular smooth muscle cells. J Biol Chem. 2000;275:22435-22441. (Pubitemid 30621831)
17. Goetze S, Kintscher U, Kim S, et al. PPARg-ligands inhibit nuclear but not cytosolic ERK MAPK-regulated steps in vascular smooth muscle cell migration. J Cardiovasc Pharmacol. 2001;38:909-921.
18. Lin AS, Nakagawa-Goto K, Chang FR, et al. First total synthesis of protoapigenone and its analogues as potent cytotoxic agents. J Med Chem. 2007;50:3921-3927. (Pubitemid 47292055)
19. Ishiyama M, Shiga M, Sasamoto K, et al. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull. 1993;41:1118-1122. (Pubitemid 23240097)
20. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322. (Pubitemid 30054364)
21. Racher AJ, Looby D, Griffiths JB. Use of lactate dehydrogenase release to assess changes in culture viability. Cytotechnology. 1990;3:301-307.
22. Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer. 2003;2: 29-50.
23. Blain SW. Switching cyclin D-Cdk4 kinase activity on and off. Cell Cycle. 2008;7:892-898. (Pubitemid 351573783)
24. Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol Ther. 2002;96:67-202. (Pubitemid 35356564)
25. Middleton EJ, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52:673-751.
26. Boumendjel A, Ronot X, Boutonnat J. Chalcones derivatives acting as cell cycle blockers: potential anticancer drugs? Curr Drug Targets. 2009; 10:363-371.
27. Aruoma OI. Free Radicals, Environmental Radiation, and Cancer. In: Bagchi D, Preuss HG, eds. Phytopharmaceuticals in Cancer Chemoprevention. Florida 33431: CRC Press LLC, 2004:79-88.
28. Kim H, Lee MJ, Kim JE, et al. Genistein suppresses tumor necrosis factoralpha- induced proliferation via the apoptotic signaling pathway in human aortic smooth muscle cells. J Agric Food Chem. 2010;58:2015-2019.
29. Kirk EA, Sutherland P, Wang SA, et al. Dietary isoflavones reduce plasma cholesterol and atherosclerosis in C57BL/6 mice but not LDL receptor-deficient mice. J Nutr. 1998;128:954-959. (Pubitemid 28280193)
30. Kapiotis S, Hermann M, Held I, et al. Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler Thromb Vasc Biol. 1997;17:2868-2874. (Pubitemid 28016034)
31. Won SM, Park YH, Kim HJ, et al. Catechins inhibit angiotensin IIinduced vascular smooth muscle cell proliferation via mitogen-activated protein kinase pathway. Exp Mol Med. 2006;38:525-534.
32. Rival Y, Puech L, Taillandier T, et al. PPAR activators and COX inhibitors selectively block cytokine-induced COX-2 expression and activity in human aortic smooth muscle cells. Eur J Pharmacol. 2009;606:121-129.
33. Stintzing S, Ocker M, Hartner A, et al. Differentiation patterning of vascular smooth muscle cells (VSMC) in atherosclerosis. Virchows Arch. 2009;455:171-185.
34. Kleinhenz JM, Kleinhenz DJ, You S, et al. Disruption of endothelial peroxisome proliferator-activated receptor-g reduces vascular nitric oxide production. Am J Physiol Heart Circ Physiol. 2009;297:H1647-H1654.
35. Meredith D, Panchatcharam M, Miriyala S, et al. Dominant-negative loss of PPAR gamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler Thromb Vasc Biol. 2009;29:465-471.
36. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol. 2000;36:1529-1535.
37. Jones A, Deb R, Torsney E, et al. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation. 2009;119:3125-3132.
38. Liu JZ, Lyon CJ, Hsueh WA, et al. A dominant-negative PPAR gamma mutant promotes cell cycle progression and cell growth in vascular smooth muscle cells. PPAR Res. 2009;2009:438673.